EN
Patient-first cell therapy innovation
 
Peripheral eosinophil counts predict efficacy of anti-CD19 CAR-T cell therapy against B-lineage non-Hodgkin lymphoma.
  • 0
Jia Q., Qin D., He F., Xie Q., Ying Z., Zhang Y., Song Y., Cheng J.N., Zuo X., Xu L., Fang H., Hu C., Peng L., Jin T., Shi Z., Alexander P.B., Wang Y., Liu Y., Han W., Zhu J., Wang P.*, Li Q.-J.*, Zhu B.* (2021) Peripheral eosinophil counts predict efficacy of anti-CD19 CAR-T cell therapy against B-lineage non-Hodgkin lymphoma. Theranostics 11(10):4699-4709. (*: Corresponding authors, PMCID: PMC7978305)

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7978305/



Copyright © 2019 TCR CURE Biopharma Technology Co., Ltd Powered by vancheer
About TCRCure
Research and Development
Products and Clinic
News and Media
Recruitment

Copyright © 2019 TCR CURE Biopharma Technology Co., Ltd Powered by vancheer